ALK Abello (ALK-B.CO)

Executive Summary

ALK Abello is a leading Danish specialty pharmaceutical company with over 100 years of expertise in allergy immunotherapy. The company has successfully pioneered tablet-based sublingual immunotherapy (SLIT) products, such as Grazax (grass pollen) and Odactra (house dust mite), which are sold in over 40 countries. ALK's strategy focuses on expanding its immunotherapy portfolio into new allergen targets, including food allergies (e.g., peanut) and respiratory allergies (e.g., ragweed, cat dander), as well as leveraging AI-driven drug discovery to enhance efficacy and patient adherence. The company reported solid revenue growth in 2025, driven by strong prescription trends for its core SLIT tablets, and maintains a robust balance sheet with a market cap of approximately $9.2 billion. Key near-term catalysts include potential US FDA approval of its cat allergy tablet, phase 3 data readout for peanut allergy immunotherapy, and expansion into emerging markets. With a deep pipeline and established commercial infrastructure, ALK is well-positioned to capture a larger share of the growing allergy treatment market.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval Decision for Cat Allergy Tablet (ALK-015)70% success
• Q2 2027Phase 3 Top-Line Results for Peanut Allergy Immunotherapy (ALK-011)60% success
• Q1 2027Commercial Launch of Tree Pollen SLIT Tablet in Japan85% success